Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status
J Clin Oncol Gordon et al. 24:4324
Publisher’s Note
The September 10, 2006, article by Gordon et al entitled, "Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status" (J Clin Oncol 24:4324-4332, 2006) was published online September 10, 2006 with errors. In Table 3, the data were incorrectly given for Survival and Progression Free Survival. This has been corrected as of May 14, 2008.
|
